Case Control in Sarcopenia Among Elderly Type 2 Diabetic Patients

1. Assess sarcopenia prevalence in elderly diabetic patients. 2. Evaluate impact of diabetes and its medications on muscle health. 3. detect effect of sacropenia on quality of life on elderly

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Sarcopenia Atrophy Muscular Atrophy Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

65 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria:

The study will included all patient ,age ≥ 60 years,diagnosed with type 2 diabetes mellitus at least 5 years duraation according to ADA guideline referance(8) (diabetes can be made if a patient's A1C is 6.5% or higher, their FPG is 126 mg/dL or higher, or their 2-hour plasma glucose during an OGTT is 200 mg/dL or higher. A random plasma glucose of 200 mg/dL or higher, in conjunction with classic symptoms of hyperglycemia, also indicates diabetes)

●Able to give informed consent

Exclusion criteria:

chronic renal disease
chronic liver disese
Severe cognitive impairment
Known neuromuscular diseases affecting mobility
malignancy Data of the study will collected over one year duration from 1/2026 _1/2027

Treatment and study plan

Muscle Ultrasound

Diagnostic Test

Bedside muscle ultrasound to measure muscle thickness, cross-sectional area and echogenicity

Primary outcomes

Prevalence of sarcopenia assessed by muscle ultrasound in elderly diabetic

Time frame: Within 6 months from the start of recruitment.

Sarcopenia will be evaluated using muscle ultrasound to measure muscle thickness and echo intensity of the quadriceps muscle. The results will be interpreted according to EWGSOP2 diagnostic criteria, which combine muscle mass and muscle strength parameters
Assessment of muscle strength using handgrip dynamometry

Time frame: Within 6 months

Handgrip strength will be measured using a handheld dynamometer, and the average of three attempts for the dominant hand will be recorded.

Secondary outcomes

Quality of life score using the SarQoL questionnaire.

Time frame: Within 6 months.

Quality of life related to sarcopenia will be evaluated using the validated SarQoL questionnaire.

Study contacts

Contact information is provided by the study sponsor or research team.

eman alaa eldean, master degree

CONTACT

[email protected]

2+01098614329

Sponsors and collaborators

Lead sponsor

Eman Alaa Eldean Mohamed

Other

Registry information

Official study title

Asessment of Sarcopenia Among Elderly Type 2 Diabetic Patients

Important dates

Study start: 2025
Primary completion: 2027
Study completion: 2028
First posted: Nov 24, 2025
Registry last updated: Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting